Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$24.66 USD
-1.04 (-4.05%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $24.66 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PTGX 24.66 -1.04(-4.05%)
Will PTGX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PTGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTGX
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
PTGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Stocks to Buy for Attractive Earnings Acceleration
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
4 Must-Buy Stocks for Remarkable Earnings Acceleration
Other News for PTGX
Protagonist Therapeutics Inc CEO Sells 25,000 Shares
Protagonist Therapeutics Earns ‘Buy’ Rating on Strong Clinical Progress and Strategic Partnerships
Protagonist expects to reach VERIFY enrollment target by end of March
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
Catalyst Watch: Walgreens earnings, UPS analyst day and Xiaomi's luxury EV debut